XML 74 R60.htm IDEA: XBRL DOCUMENT
v3.20.2

License agreements - MorphoSys (Details) $ / shares in Units, $ in Thousands, € in Millions |  | 1 Months Ended | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | --- | ---
Mar. 03, 2020 USD ($) $ / shares | Mar. 31, 2020 EUR (€) | Jan. 31, 2020 USD ($) $ / shares | Sep. 30, 2020 USD ($) | Sep. 30, 2019 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2019 USD ($) | Dec. 31, 2019 USD ($)
Unrealized gain (loss) on long term investments |  |  |  | $ (13,207) | $ 2,339 | $ 10,935 | $ 18,703 |
Long term investments |  |  |  | 222,810 |  | 222,810 |  | $ 133,657
Research and development expense |  |  |  | 438,109 | $ 281,336 | 1,809,997 | $ 841,244 |
Collaboration loss sharing |  |  |  | 14,989 |  | 30,372 |  |
ADSs |  |  |  |  |  |  |  |
Equity Method Investment, Ownership Percentage |  |  | 25.00% |  |  |  |  |
Equity Method Investment, Aggregate Cost |  |  | $ 150,000 |  |  |  |  |
Per share price | $ / shares | $ 27.65 |  | $ 41.33 |  |  |  |  |
Lock-up period |  |  | 18 months |  |  |  |  |
Discount for lack of marketability | $ 4,900 |  |  |  |  |  |  |
Fair value of shares | 95,500 |  |  |  |  |  |  |
Long term investments | 95,500 |  |  | $ 113,900 |  | $ 113,900 |  |
Research and development expense | $ 54,500 |  |  |  |  |  |  |
MorphoSys AG |  |  |  |  |  |  |  |
Upfront payment under license agreement | € |  | € 750.0 |  |  |  |  |  |
Equity Method Investment, Ownership Percentage |  |  |  | 3.00% |  | 3.00% |  |
Unrealized gain (loss) on long term investments |  |  |  | $ 900 |  | $ 18,500 |  |
Research and development expense |  |  |  | 23,800 |  | $ 51,100 |  |
Associated future global development costs from the initiation of a Phase IIb trial, if elected to co-develop (as a percentage) |  |  |  |  |  | 55.00% |  |
Accrued and other liabilities |  |  |  | 46,800 |  | $ 46,800 |  |
Profit (loss) sharing ratio |  |  |  |  |  | 50.00% |  |
Collaboration loss sharing |  |  |  | $ 15,000 |  | $ 30,400 |  |
MorphoSys AG | Development and Regulatory Milestones | Maximum |  |  |  |  |  |  |  |
Additional milestone payments under the license agreement |  |  | $ 740,000 |  |  |  |  |
MorphoSys AG | Sales and Commercial Milestones | Maximum |  |  |  |  |  |  |  |
Additional milestone payments under the license agreement |  |  | $ 315,000 |  |  |  |  |
MorphoSys AG | MorphoSys AG |  |  |  |  |  |  |  |
Funding of future development costs (as a percent) |  |  |  |  |  | 45.00% |  |
MorphoSys AG | Incyte |  |  |  |  |  |  |  |
Funding of future development costs (as a percent) |  |  |  |  |  | 55.00% |  |

X
- Definition Ratio of sharing profit and losses under the collaboration agreement. + References No definition available. + Details
Name: | incy_CollaborationAgreementProfitLossSharingRatio
Namespace Prefix: | incy_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The expense recognized during the reporting period for collaboration loss sharing. + References No definition available. + Details
Name: | incy_CollaborationLossSharingExpense
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Adjustment to the amount of discount used to measure fair value for lack of ability to convert business interests into cash quickly.. + References No definition available. + Details
Name: | incy_FairValueInputsAmountOfDiscountForLackOfMarketability
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the additional milestone payments to be made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementAdditionalMilestonePayments
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the percentage of future global development costs funded under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded
Namespace Prefix: | incy_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of the upfront payment made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementUpfrontPaymentAmountPaid
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the percentage of associated future global development costs from the initiation of a Phase IIb trial provided the entity elects to co-develop any compounds and/or indications. + References No definition available. + Details
Name: | incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds
Namespace Prefix: | incy_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period of time that the company will not sell or otherwise transfer any of the equity method shares. + References No definition available. + Details
Name: | incy_StockPurchaseAgreementLockUpPeriod
Namespace Prefix: | incy_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + References No definition available. + Details
Name: | us-gaap_AccruedLiabilitiesAndOtherLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value of the entity's equity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_EquityFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition This element represents the aggregate cost of investments accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_EquityMethodInvestmentAggregateCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714 + Details
Name: | us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_LongTermInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=incy_AmericanDepositarySharesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=incy_MorphosysAgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=incy_IncyteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |